Mastroianni Antonio, Vangeli Valeria, Greco Sonia, Urso Filippo, Greco Francesca, Chidichimo Luciana, Mauro Maria Vittoria
UOC Malattie Infettive e Tropicali, 220599Azienda Ospedaliera di Cosenza, Cosenza, Italy.
UOC Farmacia Ospedaliera, 220599Azienda Ospedaliera di Cosenza, Cosenza, Italy.
Antivir Ther. 2021 May;26(3-5):87-92. doi: 10.1177/13596535211041494. Epub 2021 Sep 17.
Oseltamivir is an orally administered antiviral medication that selectively inhibits the influenza neuraminidase enzymes that are essential for viral replication and it is active against both influenza A and B viruses. Oseltamivir is indicated for therapy or post-exposure prevention of influenza A and B. Side effects are uncommon and include mild nausea, gastrointestinal upset, dizziness, and headache. Despite widespread use, oseltamivir has not been associated with clinically apparent liver injury; however, there is growing evidence of possible toxic liver involvement during oseltamivir therapy. To the best of our knowledge, this is the first reported case in Italy linking the development of acute hepatitis and oseltamivir therapy, in a patient suffering from influenza H1N1 infection. We also present a review of the literature on cases of oseltamivir hepatotoxicity, through the consultation of PubMed database, the bibliographical references of various articles and an extensive search using Google. In view of the analyzed results, we suggest that experts should carefully consider the need for inclusion of potential serious liver reactions be added to the oseltamivir product label.
奥司他韦是一种口服抗病毒药物，它能选择性抑制对病毒复制至关重要的流感神经氨酸酶，对甲型和乙型流感病毒均有活性。奥司他韦适用于甲型和乙型流感的治疗或暴露后预防。副作用不常见，包括轻度恶心、胃肠道不适、头晕和头痛。尽管广泛使用，但奥司他韦尚未与临床上明显的肝损伤相关联；然而，越来越多的证据表明在奥司他韦治疗期间可能存在肝脏毒性。据我们所知，这是意大利首例报告的在甲型H1N1流感感染患者中，将急性肝炎的发生与奥司他韦治疗联系起来的病例。我们还通过查阅PubMed数据库、各篇文章的参考文献以及使用谷歌进行广泛搜索，对有关奥司他韦肝毒性病例的文献进行了综述。鉴于分析结果，我们建议专家应仔细考虑是否需要在奥司他韦产品标签中增加潜在严重肝脏反应的内容。
